TPTX - TPTX STOCK NEWS

Turning Point Therapeutics (NASDAQ: TPTX) is set to present at the H.C. Wainwright Virtual Precision Oncology Conference on September 24, 2020. President and CEO Athena Countouriotis, M.D., will participate in two sessions: a "fireside chat" at 10:30 a.m. ET and a precision therapy panel discussion at noon ET. The sessions will be webcast on the company's investors page.

Turning Point focuses on next-generation cancer therapies targeting genetic drivers, with lead candidate repotrectinib showing promise in clinical studies. Their innovative drug pipeline aims to address significant treatment limitations.

Turning Point Therapeutics (TPTX) announced the formation of a new scientific advisory board to aid in its early-stage research of targeted cancer therapies. Chaired by Kevan Shokat, Ph.D., the board includes notable experts from leading institutions like UCSF and The Scripps Research Institute. This initiative aims to advance the understanding of oncogenic drivers, enhancing the company's pipeline, which includes drugs targeting key cancer-related genetic alterations. The formation of this board is expected to strengthen TPTX's research capabilities and foster innovation in precision oncology.

Turning Point Therapeutics (TPTX) announced its second-quarter financial results on August 10, 2020, reporting operating expenses of $32.7 million. The company raised $374 million in May and has cash reserves of $710 million, expected to fund operations into 2023. Key developments include advancements in the TRIDENT-1 Phase 2 study of repotrectinib, with early interim data anticipated in Q3. Additionally, an exclusive agreement with Zai Lab for repotrectinib in Greater China includes a $25 million upfront payment and potential future milestones of $151 million.

Turning Point Therapeutics (NASDAQ: TPTX) announced the appointment of Heather Adams as vice president of Human Resources, effective July 27, 2020. With over 20 years of HR experience in the health care sector, Adams will oversee HR management, including talent management and staffing. Dr. Athena Countouriotis emphasized her role in developing the company's team amid a pipeline of four advancing drug candidates. The company’s ongoing clinical studies include repotrectinib for lung cancer treatment, alongside other investigational drugs targeting specific genetic alterations.

Turning Point Therapeutics (NASDAQ: TPTX) announced the appointment of Andrew Partridge as executive vice president and chief commercial officer, effective immediately. Partridge brings over 20 years of pharmaceutical sales and marketing experience, having led more than 20 commercial launches in oncology and rare diseases. His prior roles include positions at Centrexion Therapeutics and Vertex Pharmaceuticals, where he successfully launched cystic fibrosis therapies. Turning Point’s lead candidate, repotrectinib, targets key genetic drivers in cancer, with ongoing registrational studies indicating promising antitumor activity.

Turning Point Therapeutics has granted Zai Lab exclusive rights to develop and commercialize repotrectinib in Greater China, receiving a $25 million upfront payment. This deal includes potential future milestone payments up to $151 million and mid-to-high teen royalties on net sales. Repotrectinib aims to address the unmet need for patients with ROS1-positive advanced non-small cell lung cancer. The TRIDENT-1 Phase 2 study will expand to additional Chinese sites, highlighting the strategic collaboration between both companies to enhance patient access to innovative treatment options.

Turning Point Therapeutics (NASDAQ: TPTX) presented promising preclinical studies at the AACR virtual annual meeting, focusing on its lead drug candidate, repotrectinib, and next-generation ALK inhibitor, TPX-0131. Repotrectinib demonstrated potential to enhance KRAS-G12C and MEK inhibitor efficacy by inhibiting SRC, FAK, and JAK2 signaling. Additionally, TPX-0131 showed high potency against resistant ALK mutations, suggesting its viability for further study. The data highlight the innovative approach of Turning Point to target difficult-to-treat cancers effectively.

Turning Point Therapeutics (NASDAQ: TPTX) announced that President and CEO Athena Countouriotis, M.D., will participate in a Q&A session at the 41^st annual Goldman Sachs Global Healthcare Conference on June 9, starting at 4:40 p.m. ET. The session will be available via audio webcast on the company's Investors page.

Turning Point Therapeutics focuses on precision oncology, developing therapies targeting genetic drivers of cancer. Their lead candidate, repotrectinib, targets ROS1 and TRK drivers in non-small cell lung cancer, showing promising results in ongoing studies.

Turning Point Therapeutics (NASDAQ: TPTX) presented preclinical results for its selective RET inhibitor, TPX-0046, at the ASCO Annual Meeting. The studies showed TPX-0046's potent activity against various RET alterations, particularly solvent-front mutations like G810S and G810R. An ongoing Phase 1/2 trial is assessing the drug's safety and efficacy in RET TKI-naïve and pretreated patients with RET-altered cancers, aiming for a patient cohort of 350. With its unique macrocyclic structure, TPX-0046 represents a promising advancement in targeting RET-driven cancers where current options are limited.